Provectus Biopharmaceuticals, Inc.

OTC:PVCT

0.13 (USD) • At close November 27, 2023
Bedrijfsnaam Provectus Biopharmaceuticals, Inc.
Symbool PVCT
Munteenheid USD
Prijs 0.149
Beurswaarde 62,550,728
Dividendpercentage 0%
52-weken bereik 0.052 - 0.19
Industrie Biotechnology
Sector Healthcare
CEO Dr. Eric A. Wachter
Website https://www.provectusbio.com

An error occurred while fetching data.

Over Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver;

Vergelijkbare Aandelen

Pharma-Bio Serv, Inc. logo

Pharma-Bio Serv, Inc.

PBSV

0.98 USD

Cell Source, Inc. logo

Cell Source, Inc.

CLCS

0.498 USD

Vext Science, Inc. logo

Vext Science, Inc.

VEXTF

0.215 USD

CordovaCann Corp. logo

CordovaCann Corp.

LVRLF

0.121 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)